Josep Julve obtained a Ph.D. degree in Biological Sciences in 2000 under the supervision of Dr. Francisco Blanco Vaca at the Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau (IRHSCSP). In 2014, he joined the IRHSCSP after being awarded a “Miguel Servet” researcher position. His current research lines are focused on investigating the contribution of bioactive lipid species, which are constituents of the lipidome of circulating lipoproteins, in the development of NAFLD and myocardial damage in different cardiometabolic scenarios. It is worth noting that in the last five years, he started a new research line of investigation within our research group at the IRHSCSP mainly focused on the mechanisms of disease and identification of novel biomarkers from lipid metabolism and novel therapies (i.e., nutritional, pharmacologic, bariatric surgery) to combat main cardiometabolic complications of obesity and type 2 diabetes mellitus (including non-alcoholic fatty liver -NAFLD-, cardiomyopathy, and derangements in cholesterol metabolism, among others) in patients and appropriate experimental models.
Research Keywords & Expertise
Diabetes
Metabolic Syndrome
Obesity
therapeutics
Lipoprotein metabolism
Fingerprints
23%
Diabetes
16%
therapeutics
15%
Obesity
6%
Lipoprotein metabolism
5%
Metabolic Syndrome
Short Biography
Josep Julve obtained a Ph.D. degree in Biological Sciences in 2000 under the supervision of Dr. Francisco Blanco Vaca at the Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau (IRHSCSP). In 2014, he joined the IRHSCSP after being awarded a “Miguel Servet” researcher position. His current research lines are focused on investigating the contribution of bioactive lipid species, which are constituents of the lipidome of circulating lipoproteins, in the development of NAFLD and myocardial damage in different cardiometabolic scenarios. It is worth noting that in the last five years, he started a new research line of investigation within our research group at the IRHSCSP mainly focused on the mechanisms of disease and identification of novel biomarkers from lipid metabolism and novel therapies (i.e., nutritional, pharmacologic, bariatric surgery) to combat main cardiometabolic complications of obesity and type 2 diabetes mellitus (including non-alcoholic fatty liver -NAFLD-, cardiomyopathy, and derangements in cholesterol metabolism, among others) in patients and appropriate experimental models.
Advance your academic career, collaborate globally, and expand your network—
join now
!
Well done!
